Valneva SE
Specialty vaccine company developing and commercializing vaccines for infectious diseases.
VLA | PA
Overview
Corporate Details
- ISIN(s):
- AT0000A10B99 (+3 more)
- LEI:
- 969500DIVIP5VKNW4948
- Country:
- France
- Address:
- 6 RUE ALAIN BOMBARD, 44800 SAINT-HERBLAIN
- Website:
- https://valneva.com/
- Sector:
- Manufacturing
Description
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-02-03 22:30 |
Valneva Announces New $85 Million Financing Arrangement with Leading US Healthc…
|
English | 377.6 KB | ||
| 2020-02-03 22:30 |
Valneva annonce un accord de financement de $85 millions avec deux fonds US, De…
|
French | 545.9 KB | ||
| 2020-01-14 07:00 |
Valneva: le département américain de la Défense exerce l’option du contrat IXIA…
|
French | 466.7 KB | ||
| 2020-01-14 07:00 |
Valneva: US DoD Exercises Option on IXIARO® Supply Contract Bringing Total Valu…
|
English | 309.3 KB | ||
| 2020-01-09 07:00 |
Valneva poursuit le développement de ses activités commerciales avec l’ouvertur…
|
French | 547.8 KB | ||
| 2020-01-09 07:00 |
Valneva Expands its Commercial Operations with the Opening of its French Commer…
|
English | 394.7 KB | ||
| 2020-01-08 07:30 |
Bilan Semestriel du contrat de liquidité de Valneva SE
|
French | 92.5 KB | ||
| 2020-01-08 07:30 |
Déclaration d'actions et de droits de vote de la société Valneva SE - Décembre …
|
French | 16.6 KB | ||
| 2020-01-07 17:45 |
Valneva Announces End of Phase 2 Meeting with the FDA for its Chikungunya Vacci…
|
English | 395.8 KB | ||
| 2020-01-07 17:45 |
Valneva : réunion de fin de Phase 2 programmée avec la FDA pour le candidat vac…
|
French | 591.4 KB | ||
| 2019-12-12 22:45 |
Valneva Appoints MVM Partner Thomas Casdagli to its Supervisory Board
|
English | 357.8 KB | ||
| 2019-12-12 22:45 |
Valneva nomme Thomas Casdagli, Associé de la société MVM, à son Conseil de Surv…
|
French | 361.4 KB | ||
| 2019-12-09 17:40 |
Valneva annonce la nomination des spécialistes des vaccins Stanley Plotkin et A…
|
French | 353.1 KB | ||
| 2019-12-09 17:40 |
Valneva Appoints Renowned Vaccinologists Stanley Plotkin and Anna Durbin to its…
|
English | 348.4 KB | ||
| 2019-12-05 17:45 |
Valneva to Conduct Investor and Partnering Meetings during the 38th Annual J.P.…
|
English | 293.2 KB |
Automate Your Workflow. Get a real-time feed of all Valneva SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Valneva SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Valneva SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-03-18 | N/A | Other | Buy | 44,222 | N/A |
| 2024-01-03 | N/A | Other | Other | 34,802 | N/A |
| 2023-06-20 | N/A | Other | Sell | 192,547 | 1,406,228.50 EUR |
| 2023-06-19 | N/A | Other | Sell | 30,661 | 209,629.26 EUR |
| 2023-06-16 | N/A | Other | Sell | 85,589 | 582,493.06 EUR |
| 2023-06-15 | N/A | Other | Sell | 28,179 | 189,503.78 EUR |
| 2023-06-14 | N/A | Other | Sell | 228,951 | 1,519,914.11 EUR |
| 2023-06-13 | N/A | Other | Sell | 29,401 | 187,922.37 EUR |
| 2023-06-12 | N/A | Other | Sell | 117,854 | 733,782.57 EUR |
| 2023-05-10 | N/A | Other | Buy | 87,523 | N/A |
Peer Companies
